Publication:
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Simple item page
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorsAvcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B., et al.
dc.date.accessioned2023-09-18T10:55:55Z
dc.date.available2023-09-18T10:55:55Z
dc.date.issued2023-11-01
dc.description.abstractIntroduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (≥65 years) with metastatic breast cancer patients were investigated. Materials and Methods: Among older patients receiving palbociclib and ribociclib, Geriatric 8 (G8) and Groningen Frailty Index were used to evaluate frailty status. Dose modifications, drug withdrawal and other serious adverse events (SAEs) were recorded and analyzed according to baseline patient characteristics. Results: A total of 160 patients from 28 centers in Turkey were included (palbociclib = 76, ribociclib = 84). Forty-three patients were ≥ 75 years of age. The most common cause of first dose modification was neutropenia for both drugs (97% palbociclib, 69% ribociclib). Liver function tests elevation (10%) and renal function impairment (6%) were also causes for ribociclib dose modification. Drug withdrawal rate was 3.9% for palbociclib and 6% for ribociclib. SAEs were seen in 11.8% of those taking palbociclib and 15.5% of those on riboclib. An ECOG performance status of ≥2 and being older than 75 years were associated with dose reductions. Severe neutropenia was more common in patients with non-bone-only metastatic disease, those receiving treatment third-line therapy or higher, coexistance of non-neutropenic hematological side effects (for ribociclib). Neutropenia was less common among patients with obesity. Discussion: Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged ≥75 years and/or with an ECOG performance status ≥2.
dc.identifier.citationAvcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B., et al., "PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study", Journal of Geriatric Oncology, cilt.14, sa.8, 2023
dc.identifier.doi10.1016/j.jgo.2023.101604
dc.identifier.issn1879-4068
dc.identifier.issue8
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85169931836&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/293503
dc.identifier.volume14
dc.language.isoeng
dc.relation.ispartofJournal of Geriatric Oncology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectGeriatri
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectGeriatrics
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectGERİATRİ ve GERONTOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectONCOLOGY
dc.subjectGERIATRICS & GERONTOLOGY
dc.subjectGeriatri ve Gerontoloji
dc.subjectGeriatrics and Gerontology
dc.subjectAdverse events
dc.subjectBreast cancer
dc.subjectCDK 4/6 inhibitors
dc.subjectGeriatrics
dc.subjectCDK 4/6 inhibitors
dc.subjectBreast cancer
dc.subjectAdverse events
dc.titlePROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
dc.typearticle
dspace.entity.typePublication
local.avesis.ide88d5c53-80a2-4367-9e70-508cf47d2237
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication.latestForDiscovery22952072-1852-47c4-b1ff-669ac16d2ad6

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2.pdf
Size:
413.71 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs